TY - JOUR
T1 - Activin A and Acvr2b mRNA from Umbilical Cord Blood Are Not Reliable Markers of Mild or Moderate Neonatal Hypoxic-Ischemic Encephalopathy
AU - O'Sullivan, Marc Paul
AU - Denihan, Niamh
AU - Sikora, Klaudia
AU - Finder, Mikael
AU - Ahearne, Caroline
AU - Clarke, Gerard
AU - Hallberg, Boubou
AU - Boylan, Geraldine B.
AU - Murray, Deirdre M.
N1 - Funding Information:
The research was funded by the National Children’s Research Centre, Crumlin (NCRC; B/14/1), the Health Research Board (HRB; CSA/2012/40), and a Science Foundation Research Centre Award (INFANT; 12/RC/2272). GC is also funded by Science Foundation Ireland (SFI) grant number 12/RC/2273 P2.
Funding Information:
Dr. Denihan reports grants from Clinical Research Development Ireland, during the conduct of the study. Dr. Clarke reports grants from Health Research Board, grants from Air Force Office of Scientific Research, grants from Pharmavite, other from Janssen Ireland, grants from Science Foundation Ireland, outside the submitted work. Dr. Ahearne reports grants from Health Research Board, Ireland, during the conduct of the study. All the other authors report no conflict of interest.
Publisher Copyright:
© 2020 Georg Thieme Verlag. All rights reserved.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Background ?Activin A protein and its receptor ACVR2B have been considered viable biomarkers for the diagnosis of hypoxic-ischemic encephalopathy (HIE). This study aimed to assess umbilical cord blood (UCB) levels of Activin A and Acvr2b messenger RNA (mRNA) as early biomarkers of mild and moderate HIE and long-term neurodevelopmental outcome. Methods ?One-hundred and twenty-six infants were included in the analyses from the BiHiVE2 cohort, a multi-center study, recruited in Ireland and Sweden (2013 to 2015). UCB serum Activin A and whole blood Acvr2b mRNA were measured using enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, respectively. Results ?Activin A analysis included 101 infants (controls, n = 50, perinatal asphyxia, n = 28, HIE, n = 23). No differences were detected across groups (p = 0.69). No differences were detected across HIE grades (p = 0.12). Acvr2b mRNA analysis included 67 infants (controls, n = 22, perinatal asphyxia, n = 23, and HIE, n = 22), and no differences were observed across groups (p = 0.75). No differences were detected across HIE grades (p = 0.58). No differences were detected in neurodevelopmental outcome in infants followed up to 18 to 36 months in serum Activin A or in whole blood Acvr2b mRNA (p = 0.55 and p = 0.90, respectively). Conclusion ?UCB Activin A and Acvr2b mRNA are not valid biomarkers of infants with mild or moderate HIE; they are unable to distinguish infants with HIE or infants with poor neurodevelopmental outcomes.
AB - Background ?Activin A protein and its receptor ACVR2B have been considered viable biomarkers for the diagnosis of hypoxic-ischemic encephalopathy (HIE). This study aimed to assess umbilical cord blood (UCB) levels of Activin A and Acvr2b messenger RNA (mRNA) as early biomarkers of mild and moderate HIE and long-term neurodevelopmental outcome. Methods ?One-hundred and twenty-six infants were included in the analyses from the BiHiVE2 cohort, a multi-center study, recruited in Ireland and Sweden (2013 to 2015). UCB serum Activin A and whole blood Acvr2b mRNA were measured using enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, respectively. Results ?Activin A analysis included 101 infants (controls, n = 50, perinatal asphyxia, n = 28, HIE, n = 23). No differences were detected across groups (p = 0.69). No differences were detected across HIE grades (p = 0.12). Acvr2b mRNA analysis included 67 infants (controls, n = 22, perinatal asphyxia, n = 23, and HIE, n = 22), and no differences were observed across groups (p = 0.75). No differences were detected across HIE grades (p = 0.58). No differences were detected in neurodevelopmental outcome in infants followed up to 18 to 36 months in serum Activin A or in whole blood Acvr2b mRNA (p = 0.55 and p = 0.90, respectively). Conclusion ?UCB Activin A and Acvr2b mRNA are not valid biomarkers of infants with mild or moderate HIE; they are unable to distinguish infants with HIE or infants with poor neurodevelopmental outcomes.
KW - Activin A
KW - biomarkers
KW - hypoxic-ischemic encephalopathy
KW - long-term outcome
KW - neonatal encephalopathy
KW - perinatal asphyxia
UR - http://www.scopus.com/inward/record.url?scp=85102637223&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/33706404
U2 - 10.1055/s-0041-1725012
DO - 10.1055/s-0041-1725012
M3 - Article
C2 - 33706404
AN - SCOPUS:85102637223
SN - 0174-304X
VL - 52
SP - 261
EP - 267
JO - Neuropediatrics
JF - Neuropediatrics
IS - 4
ER -